NMD670
( DrugBank: NMD-670 / KEGG DRUG: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 7 |
| 10 | Charcot-Marie-Tooth disease | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 1 |
3. Spinal muscular atrophy
Clinical trials : 317 / Drugs : 217 - (DrugBank : 34) / Drug target genes : 55 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
10. Charcot-Marie-Tooth disease
Clinical trials : 59 / Drugs : 76 - (DrugBank : 12) / Drug target genes : 13 - Drug target pathways : 24
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
11. Myasthenia gravis
Clinical trials : 525 / Drugs : 355 - (DrugBank : 80) / Drug target genes : 75 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|